DHINGRA KAPIL,HIGGINS BRIAN,KOLINSKY KENNETH,LEE RICHARD J.,LESTINI BRIAN,PACKMAN KATHRYN E.,SU FEI
申请号：
NZ60625111
公开号：
NZ606251A
申请日:
2011.08.16
申请国别(地区):
NZ
年份:
2015
代理人:
摘要：
The disclosure relates to a use of a combination of propane-1-sulfonic acid { 3-[5-(4-chloro-phenyl)-1H-pyrrolo [2,3-b]pyridine-3-carbonyl]-2,4-difluoro-phenyl} -amide and an EGFR inhibitor selected from erlotinib and cetuximab, as a combined preparation adapted for the simultaneous or sequential use in the treatment of a proliferative disorder such as cancer, more particularly colorectal cancer, melanoma and thyroid cancer comprising b-Raf having a V600E mutation. The combination may further comprise a topoisomerase inhibitor such as irinotecan as a third component.
